[1] | Tomasetti C, Vogelstein B . Cancer etiology, Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science, 2015,347(6217):78-81. | [2] | Tomasetti C, Li L, Vogelstein B . Stem cell divisions, somatic mutations, cancer etiology, and cancer prevention. Science, 2017,355(6331):1330-1334. | [3] | Helleday T, Eshtad S, Nik-Zainal S . Mechanisms underlying mutational signatures in human cancers. Nat Rev Genet, 2014,15(9):585-598. | [4] | Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Børresen-Dale AL, Boyault S, Burkhardt B, Butler AP, Caldas C, Davies HR, Desmedt C, Eils R, Eyfjörd JE, Foekens JA, Greaves M, Hosoda F, Hutter B, Ilicic T, Imbeaud S, Imielinski M, Jäger N, Jones DT, Jones D, Knappskog S, Kool M, Lakhani SR, López-Otín C, Martin S, Munshi NC, Nakamura H, Northcott PA, Pajic M, Papaemmanuil E, Paradiso A, Pearson JV, Puente XS, Raine K, Ramakrishna M, Richardson AL, Richter J, Rosenstiel P, Schlesner M, Schumacher TN, Span PN, Teague JW, Totoki Y, Tutt AN Valdés-Mas R, van Buuren MM, van't Veer L, Vincent-Salomon A, Waddell N, Yates LR, Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, ICGC PedBrain, Zucman-Rossi J, Futreal PA, McDermott U, Lichter P, Meyerson M, Grimmond SM, Siebert R, Campo E, Shibata T, Pfister SM, Campbell PJ, Stratton MR. Signatures of mutational processes in human cancer. Nature, 2013,500(7463):415-421. | [5] | Prasad SR, Narra VR, Shah R, Humphrey PA, Jagirdar J, Catena JR, Dalrymple NC, Siegel CL . Segmental disorders of the nephron: histopathological and imaging perspective. Br J Radiol, 2007,80(956):593-602. | [6] | Ginsberg MS, Grewal RK, Heelan RT . Lung cancer. Radiol Clin North Am, 2007,45(1):21-43. | [7] | Zhao P, Dai M, Chen W, Li N . Cancer trends in China. Jpn J Clin Oncol, 2010,40(4):281-285. | [8] | Alexandrov LB, Nik-Zainal S, Wedge DC, Campbell PJ, Stratton MR . Deciphering signatures of mutational processes operative in human cancer. Cell Rep, 2013,3(1):246-259. | [9] | Alexandrov LB, Stratton MR . Mutational signatures: the patterns of somatic mutations hidden in cancer genomes. Curr Opin Genet Dev, 2014,24:52-60. | [10] | Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, Cole CG, Ward S, Dawson E, Ponting L, Stefancsik R, Harsha B, Kok CY, Jia M, Jubb H, Sondka Z, Thompson S, De T, Campbell PJ . COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res, 2017,45(d1):D777-D783. | [11] | Rosenthal R McGranahan N, Herrero J, Taylor BS, Swanton C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol, 2016,17:31. | [12] | Garber K . In a major shift, cancer drugs go 'tissue- agnostic'. Science, 2017,356(6343):1111-1112. | [13] | Kandoth C McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MDM, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, Wilson RK, Raphael BJ, Ding L. Mutational landscape and significance across 12 major cancer types. Nature, 2013,502(7471):333-339. |
|